CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 637 enrolled
Drug / intervention
Paclitaxel+Carboplatin +1 moredrug
Likely dose
Paclitaxel+Carboplatin 180mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00226915
NCT00226915Phase 3Completed
CompareCT.gov

Randomized Phase III Trial of Conventional Paclitaxel and Carboplatin Versus Dose Dense Weekly Paclitaxel and Carboplatin in Patients With Newly Diagnosed Stage II-IV Mullerian Carcinoma

Japanese Gynecologic Oncology Group·interventional·Posted Sep 27, 2005·Updated Feb 17, 2020

In Brief

A Phase 3 clinical trial evaluating Paclitaxel+Carboplatin for Epithelial Ovarian Cancer and 2 related conditions. Completed, enrolled 637 participants across 1 site.

Detailed Summary

The purpose of the study is to compare progression-free survival of conventional paclitaxel and carboplatin vs weekly paclitaxel and carboplatin in patients with newly diagnosed stage II-IV ovarian epithelial, primary peritoneal, or fallopian tube cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEpithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
CountriesJapan
Collaborators--

Timeline

Phase 3CompletedFinished
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 27, 2005
Enrollment StartApr 1, 2003
Primary CompletionJun 1, 2012
TodayJul 2, 2026
Enrollment to primary: 9.2 yearsPosted 20.8 years ago

Interventions

Paclitaxel+Carboplatindrug

Paclitaxel 180mg/m2＋CBDCA AUC6 q21 days x 6-9cycles

Paclitaxel+Carboplatindrug

Paclitaxel 80mg/m2 weekly ＋CBDCA AUC6 q21 days x 6-9cycles